Investigating the safety of frexalimab in adults with relapsing MS
The purpose of this study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis who are 18 to 55 years of age at the time of enrollment.